Navigation Links
MonoSol Rx Appoints Theodore Clemente Vice President Business Development

WARREN, N.J., July 23 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm((R)) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced the appointment of Theodore "Ted" Clemente, Jr. as Vice President, Business Development. Mr. Clemente will report to Keith J. Kendall, Executive Vice President and CFO.

Mr. Kendall stated, "We are pleased to welcome Ted to MonoSol Rx and look forward to benefiting from his expertise as we continue to identify and secure opportunities that leverage the unique attributes of our PharmFilm((R)) technology. Through our strategic partnerships and recent NDA submission for ondansetron orally dissolving thin film, we have validated our thin film platform and its potential to develop new, highly differentiated drug compounds that offer improved compliance, convenience and efficacy. Ted's knowledge of the pharmaceutical industry, and in particular the pressures that companies now face in trying to account for generic encroachment and pending exclusivity losses, will be instrumental as we extend our development pipeline and target additional partnership arrangements."

Prior to joining MonoSol Rx, Mr. Clemente spent the past 12 years with Novartis Consumer Health, Inc. where he most recently served as the Company's Director, Global Business Development and Licensing. While at Novartis Consumer Health, Mr. Clemente built an extensive track record identifying, negotiating and licensing a variety of drug and technology platforms. Among his numerous accomplishments, Mr. Clemente successfully led negotiations for Novartis Consumer Health to acquire exclusive U.S. rights for over-the-counter Prevacid and was responsible for closing the Company's licensing and supply agreement for Triaminic.

A 30-year veteran of the pharmaceutical industry, Mr. Clemente has also held product development and managerial positions with Ciba Self-Medication, Inc., Hoechst-Roussell Pharmaceuticals and Bristol-Myers Products. Mr. Clemente is a graduate of Rutgers College of Pharmacy, Rutgers University.

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in thin film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).

    The Ruth Group                        Contact:
    Jason Rando (media)                   MonoSol Rx
    (646) 536-7025                        Keith Kendall               Chief Financial Officer
    Sara Ephraim Pellegrino (investors)   (732) 564-5000
    (646) 536-7002

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
2. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
3. MonoSol Rx Granted U.S. Article of Manufacture Patent
4. MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
5. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
6. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
7. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
8. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
9. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
10. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
11. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
Post Your Comments:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology: